Case Report: Primary Duodenal Melanoma with Brain Metastasis

Nguyen, Sonha; Khan, Naila A; Duong, Christine; Le, Michael; Ranpura, Vishal

doi:10.7812/tpp/20.252

Cited by 2 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also summarized 10 cases published between 1990 and 2023 of primary duodenal melanoma (Table 1). [8][9][10][11][12][13][14][15][16][17] The male-to-female ratio was 8:3 and patients' age at diagnosis ranged from 35 to 68 years, with a median of 61 years. Early clinical symptoms are insidious, symptoms such as abdominal pain, dark stools and systemic wasting symptoms (weight loss and anemia) mostly occur in the middle and late stages.…”

Section: Discussionmentioning

confidence: 99%

“…The median survival time after surgery is about 28 months, and later deaths are mostly caused by distant metastases to the liver, brain, and other organs. [ 14 , 17 ] Patient 1 underwent pancreaticoduodenectomy, supplemented with BRAF inhibitor targeted therapy. This patient survived 26 months after surgery, which was consistent with reports in the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Second, third and fourth part 18 Gastrointestinal stromal tumor Yes PD 36 AWD Nguyen et al [17] 61/M Anemia, fatigue V600 is accountable for nearly Moreover, BRAF mutation is regarded as a target for tyrosine kinase inhibitor intervention in signal transduction pathway therapy, with which significant progress has been made in the treatment of malignant melanoma. [23] Therefore, the 2019 Chinese society of clinical oncology Melanoma Diagnosis and Treatment Guidelines recommend the routine detection of BRAF mutations in malignant melanoma patients, improving the significance of subsequent treatment decisions.…”

Section: Second Part 25 Poorly Differentiated Carcinomamentioning

confidence: 99%

See 2 more Smart Citations

Duodenal malignant melanoma: Primary and metastatic case series and literature review

Zhou,

Li,

Liu

et al. 2024

Medicine

View full text Add to dashboard Cite

Rationale: Duodenal malignant melanoma is rare, and its early clinical symptoms are insidious, making it difficult to diagnose in its early stages. Combined with previous literature, We explored the clinicopathological characteristics and v-raf murine sarcoma viral oncogene homolog B1 mutations in primary and metastatic duodenal malignant melanoma, in order to provide some experience on its differential diagnosis and treatment. Patient concerns: The 2 patients (a 63-year-old female [Patient 1] and a 54-year-old male [Patient 2]) experienced pain and discomfort in their upper abdomen. Additionally, one of them had a history of skin malignant melanoma. Diagnoses: Patient 1 was diagnosed with primary duodenal malignant melanoma; and Patient 2 was diagnosed with metastatic duodenal malignant melanoma. Interventions: Patient 1 underwent pancreaticoduodenectomy; and patient 2 underwent complete surgical resection and lymph node dissection. Outcomes: After surgery, Patient 1 survived after 26 months follow-up, and Patient 2 died of systemic multi-organ circulatory failure after 1 month follow-up. Lessons: Primary and metastatic cases should be diagnosed through previous medical history analysis and detailed physical and auxiliary examinations. This would enable a diagnosis based on characteristic histomorphology and immunohistochemical markers. An early diagnosis and surgical treatment can prolong patient survival and the molecular inspection of v-raf murine sarcoma viral oncogene homolog B1 mutations can guide follow-up treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Second Part 25 Poorly Differentiated Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

Duodenal malignant melanoma: Primary and metastatic case series and literature review

Zhou,

Li,

Liu

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Furthermore, after detailed physical examination, videography, and colonoscopy, no obvious lesions or nodules were found. We also summarized 10 cases published between 1990 and 2023 of primary duodenal melanoma (Table) [8][9][10][11][12][13][14][15][16][17]. The male-to-female ratio was 8:3 and patients' age at diagnosis ranged from 35 to 68 years, with a median of 61 years.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis of primary cases is slightly better than that of metastatic cases. The median survival time after surgery is about 28 months, and later deaths are mostly caused by distant metastases to the liver, brain, and other organs [14,17].Patient 1 underwent pancreaticoduodenectomy, supplemented with BRAF inhibitor targeted therapy. This patient survived 26 months after surgery, which was consistent with reports in the literature.…”

Section: Discussionmentioning

confidence: 99%

Duodenal Malignant Melanoma：Primary and Metastatic

zhou,

Li,

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Duodenal malignant melanoma is rare, and its early clinical symptoms are insidious, making it difficult to diagnose in its early stages. Methods We explored the clinicopathological characteristics of duodenal malignant melanomas and association with BRAF mutations. Hematoxylin and eosin staining, immunohistochemical marker detection, and BRAF V600E mutation inspection via Sanger sequencing for two clinical cases of duodenal malignant melanoma were performed. The relevant literature was reviewed, and the clinical pathology was analyzed. Results The two patients (a 63-year-old female [Patient 1] and a 54-year-old male [Patient 2]) experienced pain and discomfort in their upper abdomen; moreover, they had endoscopic space-occupying lesions in the second part of their duodenum and invasively growing solid sheets of round, oval, or polygonal microscopic atypical tumor. Additionally, one of them had skin malignant melanoma and pigmentation, whereas the other was positive for BRAF V600E mutation. Tumor cell immunohistochemical analysis detected Vim, HMB45, Melan-A, and S-100 positive expression. They both underwent surgical treatment; however, Patients 1 and 2 died after 1 and 28 months, respectively. Conclusion Primary and metastatic cases should be diagnosed through previous medical history analysis and detailed physical and auxiliary examinations. This would enable a diagnosis based on characteristic histomorphology and immunohistochemical markers. An early diagnosis and surgical treatment can prolong patient survival and the molecular inspection of BRAF mutations can guide follow-up treatment.

show abstract

Case Report: Primary Duodenal Melanoma with Brain Metastasis

Cited by 2 publications

References 24 publications

Duodenal malignant melanoma: Primary and metastatic case series and literature review

Duodenal malignant melanoma: Primary and metastatic case series and literature review

Duodenal Malignant Melanoma：Primary and Metastatic

Contact Info

Product

Resources

About